Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options
Open Access
- 7 May 2017
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. XX (XX), 1-10
- https://doi.org/10.14218/jcth.2016.00069
Abstract
Hepatic encephalopathy is a spectrum of reversible neuropsychiatric abnormalities, seen in patients with liver dysfunction and/or portosystemic shunting. One of the most debilitating complications of cirrhosis, encephalopathy affects 30–45% of cirrhotics. In addition to significantly affecting the lives of patients and their caregivers, it is also associated with increased morbidity and mortality as well as significant utilization of health care resources. In this paper, we provide an overview on the pathophysiology, diagnosis, management and newer therapies of hepatic encephalopathy.Keywords
This publication has 76 references indexed in Scilit:
- Gut microbiota drive the development of neuroinflammatory response in cirrhosis in miceJournal of Hepatology, 2016
- Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in FranceTherapeutic Advances in Gastroenterology, 2016
- Radiographical findings in patients with liver cirrhosis and hepatic encephalopathyGastroenterology Report, 2015
- The impact of pretransplant hepatic encephalopathy on survival following liver transplantationLiver Transplantation, 2015
- Low Likelihood of Intracranial Hemorrhage in Patients With Cirrhosis and Altered Mental StatusClinical Gastroenterology and Hepatology, 2015
- Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long‐term outcomes in 14 patientsHepatology Research, 2013
- Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia ConcentrationClinical Pharmacology in Drug Development, 2013
- Variations in the Promoter Region of the Glutaminase Gene and the Development of Hepatic Encephalopathy in Patients With CirrhosisAnnals of Internal Medicine, 2010
- Predictors of the recurrence of hepatic encephalopathy in lactulose‐treated patientsAlimentary Pharmacology & Therapeutics, 2010
- Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.1992